Johnson & Johnson to Buy Firefly Bio for $1 Billion to Expand Cancer Drug Pipeline
Johnson & Johnson will acquire Firefly Bio for $1 billion in cash, adding a new platform aimed at KRAS-driven tumors and strengthening its oncology pipeline.
medicine
Read more